aod9604 stimulates lipolysis AOD 9604: Peptide Claims vs Clinical Reality AOD 9604 is marketed as a fat-metabolism peptide derived from a growth hormone fragment, often positioned as “HGH-like” without HGH's side effects. The clinical question Treatment:3 Months AOD-9604 was developed from B-12 Injection

aod9604 stimulates lipolysis AOD 9604: Peptide Claims vs Clinical Reality AOD 9604 is marketed as a fat-metabolism peptide derived from a growth hormone fragment, often positioned as “HGH-like” without HGH's side effects. The clinical question Treatment:3 Months AOD-9604 was developed from B-12 Injection

AOD-9604 was developed from a fragment of human growth hormone because preclinical research suggested effects on fat metabolism. The human evidence did not confirm a consistent, clinically meaningful weight-loss benefit. Development was

Maintenance doses studied: 1 mg weekly (low-dose arm in Phase 2, produced -8.7% body weight loss at 48 weeks) 4 mg weekly (moderate dose, Phase 2, produced -17.1% weight loss) 8 mg weekly (Phase 2) 9 mg weekly (Phase 3 TRIUMPH trials) 12 mg weekly (maximum studied dose) Phase 3 titration protocol (TRIUMPH program): The standardized Phase 3 escalation follows 4-week steps: 2 mg → 4 mg → 6 mg → 8 mg → 10 mg → 12 mg, reaching the maximum dose by week 20

B-12 Injection

Treatment:3 Months

it does not force the body to oxidize it